Venetoclax for AML: changing the treatment paradigm.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2019000937
Abstract: Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of apoptosis in malignancies, the survival of which depends on dysregulation of this pathway. Preclinical data, using various model systems including cell lines… read more here.
Keywords: venetoclax; venetoclax aml; treatment paradigm; changing treatment ... See more keywords